Work is being conducted on the search for new formulations of Heberprot-P for the treatment of diabetic foot ulcers, while a new clinical trial is in preparation for bilateral symmetrical neuropathy.
The Cimavax-EGF® vaccine is currently undergoing a clinical trial for the treatment of patients with premalignant lesions.
CIGB 500, a peptide with cardiac cytoprotective action, is aimed at reducing the extent of myocardial infarction and protecting epithelial tissues from damage caused by ischemia-reperfusion events, according to the Cuban press.
In the area of oncology, Cuba has the Savax Active Immunotherapy project, an innovative product with an antiangiogenic effect, since it reduces the formation of blood vessels in carcinoma and, therefore, inhibits its growth. The list of novelties includes the JM-20 chemical compound, for use in Neurology, which has therapeutic potential for use in brain disorders, including Parkinson’s and Alzheimer’s.
Cuba is developing a conjugate vaccine that protects the Cuban child population from the Streptococcus pneumonia, the main pathogen that causes infectious bacterial diseases.
Other innovative products in development are the CIGB-814 peptide, for application in the therapy of autoimmune diseases, while the CIGB-845 peptide can be used in the treatment of neurological diseases.
Cuba is also working on other projects such as Amylovis (Alzheimer’s Disease), IL2 Muteins (cancer immunotherapy), NeuroEpo (treatment of neurodegenerative diseases) and Nasvac (active immunotherapy for chronic Hepatitis B).
pgh/llp/rgh/joe
